Skip to main content
. Author manuscript; available in PMC: 2016 Dec 19.
Published in final edited form as: Obstet Gynecol. 2015 Apr;125(4):833–842. doi: 10.1097/AOG.0000000000000643

Fig. 1.

Fig. 1

A. Five-year ovarian cancer–specific survival stratified according to adherence (group 1 adherent, n = 3,109) or non-adherence (group 2 nonadherent, n = 7,187) to National Comprehensive Cancer Network treatment guidelines for advanced-stage ovarian cancer. For patients receiving guideline adherent care, the median survival time (36.0 months, 95% confidence interval 35.0–38.0 months) was significantly longer compared with non–guideline-adherent care (9.0 months, 95% confidence interval 9.0–10.0 months) (log-rank P < .001). B. Estimated hazard function (probability of ovarian cancer–related mortality) plotted against follow-up time (2-month intervals) stratified according to adherence (group 1 adherent, n = 3,109) or nonadherence (group 2 nonadherent, n = 7,187) to National Comprehensive Cancer Network treatment guidelines for advanced-stage ovarian cancer showing an increased probability of death during the first 18 months of observation for patients in the nonadherent treatment group.